What is Fuller Laboratories?
Fuller Laboratories is a distinguished entity in the diagnostics industry, specializing in the development of advanced clinical and veterinary assays for the detection of vector-borne and zoonotic diseases. Boasting over three decades of expertise, the company has earned a reputation for its pioneering infectious disease immunoassays, characterized by exceptional sensitivity, specificity, and repeatability. Their product portfolio, designed for reference laboratories, encompasses a variety of assay formats, including IFA, MIF, and ELISA, serving both international markets and laboratories within the U.S. and Canada.
How much funding has Fuller Laboratories raised?
Fuller Laboratories has raised a total of $514K across 2 funding rounds:
Debt
$150K
Debt
$364K
Debt (2020): $150K with participation from PPP
Debt (2021): $364K led by PPP
Key Investors in Fuller Laboratories
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Fuller Laboratories?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Fuller Laboratories for accelerated growth and market expansion. This capital infusion is likely to fuel further research and development into novel diagnostic solutions, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's focus on high-demand areas like vector-borne and zoonotic diseases, coupled with its established reputation, suggests a trajectory aimed at solidifying its leadership in the clinical and veterinary diagnostics landscape.
See full Fuller Laboratories company page
